Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BLNE vs BHST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BHST Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

BHST Overall Winner 6-Pillar Tally: BLNE 1 – 5 BHST Matrix Metrics: BLNE 4 – 6 BHST

As of Nov 20, 2026, BioHarvest Sciences Inc. (BHST) is the stronger overall head-to-head candidate over Beeline Holdings, Inc. (BLNE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BLNE carries a Unified Composite Score of 43.4/100 (HOLD) at $0.29 (5.5x Forward P/E, -179.8% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin).

  • Growth vs. Quality Trade-Off: BHST earns the overall head-to-head edge with a stronger Unified Composite Score (58.2/100 HOLD vs. BLNE 43.4/100 HOLD) and 0.25β · 86% Vol risk profile, whereas BLNE leads top-line expansion (+29.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BLNE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.1); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLNE vs BHST
BLNE NASDAQ
Beeline Holdings, Inc. Common Stock
Mortgage Bankers & Loan Correspondents
$0.29
-21.72% 1D
Market Cap $13.1M
TTM Revenue $12M
Forward P/E 5.5x
Beta / 30D Vol 2.74β · 123% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.6%), weak momentum, RSI 19
RSI-14: 19.1 · SMA20: $0.57 · SMA50: $0.73
BHST NASDAQ Head-to-Head Winner
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58

6-Pillar Scorecard Institutional Category Breakdown (BLNE 1 – 5 BHST)

Columns: Metric · BLNE · BHST
1. Valuation Multiples BLNE
Forward P/E 5.5x N/M
Trailing P/E 5.5x N/M
PEG Ratio N/M N/M
EV / Revenue 2.5x 0.7x
2. Growth & Scale BHST
Revenue Growth (YoY) +29.8% +3.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $12M $35M
Market Cap $13.1M $29.9M
3. Profitability & Quality BHST
Gross Margin 100.0% 59.0%
Operating Margin -179.8% -18.0%
Net Profit Margin -185.9% -31.2%
Return on Equity (ROE) -42.4% -142.5%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$24M -$9.4M
Cash Flow Margin N/A -26.6%
Net Cash / Leverage $15M Net Debt (0.34x D/E) $5.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHST
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity N/A 77.0% of Rev ($27M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Mortgage Finance Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLNE (4) vs BHST (6)
Institutional Metric BLNE BHST Criterion Row Edge
Market Capitalization
Scale
$13.1M $29.9M Larger Scale BHST
Trailing P/E Ratio
Valuation
5.5x N/M Lower Multiple BLNE
Forward P/E Ratio
Valuation
5.5x N/M Lower Multiple BLNE
Revenue Growth (YoY)
Growth
+29.8% +3.8% Higher Growth BLNE
Operating Margin (TTM)
Profitability
-179.8% -18.0% Higher Margin BHST
Net Profit Margin
Profitability
-185.9% -31.2% Higher Margin BHST
Return on Equity (ROE)
Capital Efficiency
-42.4% -142.5% Higher ROE BLNE
52-Week Range Position
Momentum
0% ($0–$4) 6% ($1–$7) Stronger Trend BHST
Beta / 30D Volatility
Risk Regime
2.74β · 123% Vol 0.25β · 86% Vol Lower Realized Risk BHST
Unified Institutional Score
Composite Signal
43.4 / 100 (HOLD) 58.2 / 100 (HOLD) Higher Composite BHST
Trailing 12M Revenue (USD)
Operating Scale
$12M $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 59.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.5x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($15M Net Debt (0.34x D/E)) -$9.4M ($5.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHST +34.89 pp
BLNE: -57.51% · BHST: -22.62%
3M Horizon BHST +33.9 pp
BLNE: -70.49% · BHST: -36.59%
6M Horizon BHST +9.13 pp
BLNE: -75.45% · BHST: -66.32%
1Y Horizon BHST +1.41 pp
BLNE: -80.81% · BHST: -79.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BLNE Revenue BHST Revenue BLNE Op. Margin BHST Op. Margin Margin Leader
FY2018 $10M N/A -114.7% N/A BLNE
FY2019 $10M N/A -81.6% N/A BLNE
FY2020 $10M N/A -55.4% N/A BLNE
FY2021 $10M N/A -55.7% N/A BLNE
FY2022 $10M N/A -47.9% N/A BLNE
FY2023 $10M $10M -23.1% -78.6% BLNE
FY2024 $0M $30M -467.0% -27.7% BHST
FY2025 $10M $30M -251.5% -16.2% BHST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLNE BREAKDOWN
102d in phase · OBV DISTRIBUTION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BLNE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLNE Moat Profile Cyclical / Execution-Driven Positioning
Mortgage Finance Operator
Competes within the Mortgage Finance value chain with $13.1M market capitalization and -179.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published

Investor FAQ BLNE vs BHST Key Questions & Quantitative Answers

As of Nov 20, 2026, BioHarvest Sciences Inc. (BHST) is the stronger overall head-to-head candidate over Beeline Holdings, Inc. (BLNE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BLNE carries a Unified Composite Score of 43.4/100 (HOLD) at $0.29 (5.5x Forward P/E, -179.8% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin). Growth vs. Quality Trade-Off: BHST earns the overall head-to-head edge with a stronger Unified Composite Score (58.2/100 HOLD vs. BLNE 43.4/100 HOLD) and 0.25β · 86% Vol risk profile, whereas BLNE leads top-line expansion (+29.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BLNE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.1); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHST leads the Growth & Scale pillar: BLNE posts +29.8% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (100.0% gross margin, -179.8% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLNE cumulative revenue shifted +0.0% while BHST shifted +200.0%. In operating R&D and SG&A reinvestment, BLNE deploys N/A (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.

BLNE screens cheaper on headline valuation multiples. BLNE trades at 5.5x Forward P/E, 5.5x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (unreported FCF margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLNE (-42.4% ROE) versus BHST (-142.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BLNE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.74β · 123% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.